Human multidrug resistant KB cells overexpress protein kinase C: involvement in drug resistance.
Among the many phenotypic characteristics of multidrug resistance (MDR), the presence of P-glycoprotein is nearly always observed, and it appears that the plasma membrane of the multidrug resistant cell is integrally involved in controlling drug resistance. Another membrane-associated protein kinase, protein kinase C (PKC), has been shown to regulate the flow of information to the cell interior and to control the efflux of a number of different compounds. We therefore initiated a study of PKC and MDR. We found that multidrug resistant sublines from both mouse sarcoma 180 and human KB lines exhibited 80-90% increases in basal PKC activity. The mechanism of the increase appears to be quite different in the two cell lines. The human KB cells overexpress the alpha isozyme of PKC, commensurate with the increase in alpha-PKC protein, whereas the mouse cells do not overexpress alpha-mRNA but increase alpha-PKC protein. Furthermore, it appears that PKC activity plays a functional role in drug resistance, since inhibition of endogenous PKC activity by staurosporine resulted in decreased resistance to Adriamycin. We also found that phosphorylation of MDR cell membrane vesicles by purified PKC, followed by immunoprecipitation of P-glycoprotein with monoclonal antibody C219, resulted in a level of phosphorylation of P-glycoprotein that was greater than the endogenous phosphorylation level. The data presented indicate that MDR cells of diverse species exhibited enhanced PKC activity but that the mechanisms were different. The increased kinase activity may have biological relevance to MDR since PKC appears to be coupled to P-glycoprotein function.
Posada
J A
JA
Department of Pharmacology, University of Vermont, Burlington 05405.
McKeegan
E M
EM
Worthington
K F
KF
Morin
M J
MJ
Jaken
S
S
Tritton
T R
TR
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000470:Alkaloids / Q000494:pharmacology; D000818:Animals; D004317:Doxorubicin / Q000494:pharmacology*; D004351:Drug Resistance; D006801:Humans; D007527:Isoenzymes / Q000096:biosynthesis / Q000235:genetics; D007624:KB Cells; D007700:Kinetics; D008562:Membrane Glycoproteins / Q000302:isolation & purification*; D051379:Mice; D009363:Neoplasm Proteins / Q000302:isolation & purification*; D011493:Protein Kinase C / Q000096:biosynthesis / Q000235:genetics* / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000302:isolation & purification; D012510:Sarcoma 180 / Q000201:enzymology; D019311:Staurosporine
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000470:Alkaloids; D007527:Isoenzymes; D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D004317:Doxorubicin; D011493:Protein Kinase C; D019311:Staurosporine